Marina Badenes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marina Badenes has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Duarte
Centro Interdisciplinar de Investigação em Sanidade Animal (CIISA), University of Lisbon, Lisbon, Portugal.
6 shared publications - Alexandre Trindade
Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511 Almada, Portugal
5 shared publications - Colin Adrain
Johnston Centre for Cancer Research, Queen’s University Belfast, 97 Lisburn Rd., Belfast BT9 7BL, United Kingdom
5 shared publications Abdulbasit Amin
Gulbenkian Institute for Molecular Medicine (GIMM) Lisbon Portugal
3 shared publications- Ana Neves-Costa
Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian de Ciencia, 2780-156 Oeiras, Portugal
2 shared publications - Dora Pedroso
Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian de Ciencia, 2780-156 Oeiras, Portugal
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in BMC Cancer
ADAM17 pathway promotes canine mammary tumor cell migration
Background: ADAM17, also known as tumor necrosis factor-converting enzyme (TACE), is a pleiotropic protease that contributes to inflammation and cancer progression by activating epidermal growth factor receptor (EGFR) signaling and IL-6 trans-signaling, among other pathways. Because ADAM17 signaling remains poorly characterized in veterinary pathophysiology, we investigated its biological roles in canine mammary tumors (CMTs), one of the most common cancers in dogs, where treatment options remain limited. Methods: ADAM17 mRNA levels were compared between canine mammary carcinoma tissues and normal mammary glands. We also investigated the effects of pharmacological stimulation and/or inhibition of the ADAM17 pathway on key cancer-related biological processes in the FR37-CMT and the FR10-CMT cell lines. Specifically, we assessed cell viability and apoptosis under basal conditions and following doxorubicin treatment. In addition, we examined the impact of ADAM17 pathway modulation on epithelial-to-mesenchymal transition (EMT) and cell motility. Results: ADAM17 mRNA expression was significantly upregulated in canine mammary carcinoma tissues with grade II or more compared with normal controls, and its expression may be associated with tumor progression and dissemination. ADAM17 did not appear to play a major role in FR37-CMT cell viability, apoptosis, doxorubicin-mediated cytotoxicity, or EMT. However, ADAM17 was found to promote FR37-CMT and FR10-CMT cell motility. Conclusions: These findings suggest that pharmacological inhibition of ADAM17 activity may represent a promising strategy to limit the metastatic spread of mammary cancer in dogs.
- 28 September 2026
- Published by Springer Nature in BMC Cancer
Open AccessADAM17 pathway promotes canine mammary tumor cell migration
Background: ADAM17, also known as tumor necrosis factor-converting enzyme (TACE), is a pleiotropic protease that contributes to inflammation and cancer progression by activating epidermal growth factor receptor (EGFR) signaling and IL-6 trans-signaling, among other pathways. Because ADAM17 signaling remains poorly characterized in veterinary pathophysiology, we investigated its biological roles in canine mammary tumors (CMTs), one of the most common cancers in dogs, where treatment options remain limited. Methods: ADAM17 mRNA levels were compared between canine mammary carcinoma tissues and normal mammary glands. We also investigated the effects of pharmacological stimulation and/or inhibition of the ADAM17 pathway on key cancer-related biological processes in the FR37-CMT and the FR10-CMT cell lines. Specifically, we assessed cell viability and apoptosis under basal conditions and following doxorubicin treatment. In addition, we examined the impact of ADAM17 pathway modulation on epithelial-to-mesenchymal transition (EMT) and cell motility. Results: ADAM17 mRNA expression was significantly upregulated in canine mammary carcinoma tissues with grade II or more compared with normal controls, and its expression may be associated with tumor progression and dissemination. ADAM17 did not appear to play a major role in FR37-CMT cell viability, apoptosis, doxorubicin-mediated cytotoxicity, or EMT. However, ADAM17 was found to promote FR37-CMT and FR10-CMT cell motility. Conclusions: These findings suggest that pharmacological inhibition of ADAM17 activity may represent a promising strategy to limit the metastatic spread of mammary cancer in dogs.
- Open Access
- 23 March 2026
- Published by Wiley in The FEBS Journal
ADAM17 and its proteolytic targets in disease pathogenesis
ADAM17, from the disintegrin and metalloproteinase (ADAM) family, also called tumor necrosis factor converting enzyme (TACE), is a pleiotropic protease with more than 90 substrates, including growth factors, cytokines, receptors, and adhesion molecules. The biology of ADAM17 has been extensively studied, mainly as a regulator of epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) signaling pathways, which are crucial for growth and inflammation, respectively. Consequently, this protease has been considered a major target to treat human cancers and inflammatory disorders. Moreover, it is involved in the pathobiology of numerous other disease types. This review summarizes the current understanding of ADAM17 and the involvement of its targets in inflammation, cancer, and cardiovascular and metabolic diseases.
- 23 March 2026
- Published by Wiley in The FEBS Journal
Open AccessADAM17 and its proteolytic targets in disease pathogenesis
ADAM17, from the disintegrin and metalloproteinase (ADAM) family, also called tumor necrosis factor converting enzyme (TACE), is a pleiotropic protease with more than 90 substrates, including growth factors, cytokines, receptors, and adhesion molecules. The biology of ADAM17 has been extensively studied, mainly as a regulator of epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) signaling pathways, which are crucial for growth and inflammation, respectively. Consequently, this protease has been considered a major target to treat human cancers and inflammatory disorders. Moreover, it is involved in the pathobiology of numerous other disease types. This review summarizes the current understanding of ADAM17 and the involvement of its targets in inflammation, cancer, and cardiovascular and metabolic diseases.
- Open Access
- 20 December 2024
- Published by Wolters Kluwer Health in Regenerative Medicine Reports
- Vol. 1 (2) , 172-186
Epidermal growth factor receptor pathway in central nervous system regenerative medicine: a narrative review
The epidermal growth factor receptor (signaling pathway is involved in numerous important mammal cell functions, such as growth, survival, proliferation, and differentiation. Associated with this, it is involved in tissue normal development and growth, tumorigenesis, and in tissue repair. Epidermal growth factor receptor is broadly expressed in the organism, including in the central and peripheral nervous system, where it has important neurotrophic functions. The central nervous system has a limited capacity for regeneration upon lesion, leading to severe disabilities, such as blindness, sensorimotor deficits, and paralysis. However, observations suggest that its innate neurogenic response may be amplified to promote the replenishment of damaged neuronal populations. In addition, the environment can also be modulated to promote regeneration. Therefore, the pathways involved in neural tissue repair have been investigated in terms of regenerative medicine, to discover new therapies to recover from traumatic injury or ischemia in the central nervous system or to inhibit the progression of neurodegenerative diseases. Growth factors have been widely accepted as the most important promoters of proliferation and neurogenesis under physiologic conditions and after injury. In this review, we summarize how the epidermal growth factor receptor signaling pathway is involved in neuronal damage and neurodegeneration in several settings, including in the olfactory epithelium, brain, spinal cord, and optic nerve, where this pathway can be modulated in the context of regenerative medicine to promote neuronal regeneration and, therefore, neurological function reestablishment in response to insults.
- 20 December 2024
- Published by Wolters Kluwer Health in Regenerative Medicine Reports
- Vol. 1 (2) , 172-186
Open AccessEpidermal growth factor receptor pathway in central nervous system regenerative medicine: a narrative review
The epidermal growth factor receptor (signaling pathway is involved in numerous important mammal cell functions, such as growth, survival, proliferation, and differentiation. Associated with this, it is involved in tissue normal development and growth, tumorigenesis, and in tissue repair. Epidermal growth factor receptor is broadly expressed in the organism, including in the central and peripheral nervous system, where it has important neurotrophic functions. The central nervous system has a limited capacity for regeneration upon lesion, leading to severe disabilities, such as blindness, sensorimotor deficits, and paralysis. However, observations suggest that its innate neurogenic response may be amplified to promote the replenishment of damaged neuronal populations. In addition, the environment can also be modulated to promote regeneration. Therefore, the pathways involved in neural tissue repair have been investigated in terms of regenerative medicine, to discover new therapies to recover from traumatic injury or ischemia in the central nervous system or to inhibit the progression of neurodegenerative diseases. Growth factors have been widely accepted as the most important promoters of proliferation and neurogenesis under physiologic conditions and after injury. In this review, we summarize how the epidermal growth factor receptor signaling pathway is involved in neuronal damage and neurodegeneration in several settings, including in the olfactory epithelium, brain, spinal cord, and optic nerve, where this pathway can be modulated in the context of regenerative medicine to promote neuronal regeneration and, therefore, neurological function reestablishment in response to insults.
- 29 April 2024
- Published by Wiley in The FEBS Journal
- Vol. 291 (10) , 2094-2097
Can the HB‐EGF/EGFR pathway restore injured neurons?
Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a transmembrane protein that, when cleaved by metalloproteases through a process called ectodomain shedding, binds to the EGF receptor (EGFR), activating downstream signaling. The HB‐EGF/EGFR pathway is crucial in development and is involved in numerous pathophysiological processes. In this issue of The FEBS Journal, Sireci et al. reveal a previously unexplored function of the HB‐EGF/EGFR pathway in promoting neuronal progenitor proliferation and sensory neuron regeneration in the zebrafish olfactory epithelium in response to injury.
- 29 April 2024
- Published by Wiley in The FEBS Journal
- Vol. 291 (10) , 2094-2097
Can the HB‐EGF/EGFR pathway restore injured neurons?
Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a transmembrane protein that, when cleaved by metalloproteases through a process called ectodomain shedding, binds to the EGF receptor (EGFR), activating downstream signaling. The HB‐EGF/EGFR pathway is crucial in development and is involved in numerous pathophysiological processes. In this issue of The FEBS Journal, Sireci et al. reveal a previously unexplored function of the HB‐EGF/EGFR pathway in promoting neuronal progenitor proliferation and sensory neuron regeneration in the zebrafish olfactory epithelium in response to injury.
- Open Access
- 7 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
RHBDL4-triggered downregulation of COPII adaptor protein TMED7 suppresses TLR4-mediated inflammatory signaling
The toll-like receptor 4 (TLR4) is a central regulator of innate immunity that primarily recognizes bacterial lipopolysaccharide cell wall constituents to trigger cytokine secretion. We identify the intramembrane protease RHBDL4 as a negative regulator of TLR4 signaling. We show that RHBDL4 triggers degradation of TLR4’s trafficking factor TMED7. This counteracts TLR4 transport to the cell surface. Notably, TLR4 activation mediates transcriptional upregulation of RHBDL4 thereby inducing a negative feedback loop to reduce TLR4 trafficking to the plasma membrane. This secretory cargo tuning mechanism prevents the over-activation of TLR4-dependent signaling in an in vitro Mycobacterium tuberculosis macrophage infection model and consequently alleviates septic shock in a mouse model. A hypomorphic RHBDL4 mutation linked to Kawasaki syndrome, an ill-defined inflammatory disorder in children, further supports the pathophysiological relevance of our findings. In this work, we identify an RHBDL4-mediated axis that acts as a rheostat to prevent over-activation of the TLR4 pathway.
- 7 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessRHBDL4-triggered downregulation of COPII adaptor protein TMED7 suppresses TLR4-mediated inflammatory signaling
The toll-like receptor 4 (TLR4) is a central regulator of innate immunity that primarily recognizes bacterial lipopolysaccharide cell wall constituents to trigger cytokine secretion. We identify the intramembrane protease RHBDL4 as a negative regulator of TLR4 signaling. We show that RHBDL4 triggers degradation of TLR4’s trafficking factor TMED7. This counteracts TLR4 transport to the cell surface. Notably, TLR4 activation mediates transcriptional upregulation of RHBDL4 thereby inducing a negative feedback loop to reduce TLR4 trafficking to the plasma membrane. This secretory cargo tuning mechanism prevents the over-activation of TLR4-dependent signaling in an in vitro Mycobacterium tuberculosis macrophage infection model and consequently alleviates septic shock in a mouse model. A hypomorphic RHBDL4 mutation linked to Kawasaki syndrome, an ill-defined inflammatory disorder in children, further supports the pathophysiological relevance of our findings. In this work, we identify an RHBDL4-mediated axis that acts as a rheostat to prevent over-activation of the TLR4 pathway.
- 1 January 2024
- Published by ALIES in Biomedical and Biopharmaceutical Research
- Vol. 20 (2) , 1-13
2023 CBIOS Scientific Seminars - Book of Abstracts
- 1 January 2024
- Published by ALIES in Biomedical and Biopharmaceutical Research
- Vol. 20 (2) , 1-13
2023 CBIOS Scientific Seminars - Book of Abstracts
- Open Access
- 31 January 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (4) , e202201644
The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth
The metalloprotease ADAM17 is a sheddase of key molecules, including TNF and epidermal growth factor receptor ligands. ADAM17 exists within an assemblage, the “sheddase complex,” containing a rhomboid pseudoprotease (iRhom1 or iRhom2). iRhoms control multiple aspects of ADAM17 biology. The FERM domain–containing protein iTAP/Frmd8 is an iRhom-binding protein that prevents the precocious shunting of ADAM17 and iRhom2 to lysosomes and their consequent degradation. As pathophysiological role(s) of iTAP/Frmd8 have not been addressed, we characterized the impact of iTAP/Frmd8 loss on ADAM17-associated phenotypes in mice. We show that iTAP/Frmd8 KO mice exhibit defects in inflammatory and intestinal epithelial barrier repair functions, but not the collateral defects associated with global ADAM17 loss. Furthermore, we show that iTAP/Frmd8 regulates cancer cell growth in a cell-autonomous manner and by modulating the tumor microenvironment. Our work suggests that pharmacological intervention at the level of iTAP/Frmd8 may be beneficial to target ADAM17 activity in specific compartments during chronic inflammatory diseases or cancer, while avoiding the collateral impact on the vital functions associated with the widespread inhibition of ADAM17.
- 31 January 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (4) , e202201644
Open AccessThe ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth
The metalloprotease ADAM17 is a sheddase of key molecules, including TNF and epidermal growth factor receptor ligands. ADAM17 exists within an assemblage, the “sheddase complex,” containing a rhomboid pseudoprotease (iRhom1 or iRhom2). iRhoms control multiple aspects of ADAM17 biology. The FERM domain–containing protein iTAP/Frmd8 is an iRhom-binding protein that prevents the precocious shunting of ADAM17 and iRhom2 to lysosomes and their consequent degradation. As pathophysiological role(s) of iTAP/Frmd8 have not been addressed, we characterized the impact of iTAP/Frmd8 loss on ADAM17-associated phenotypes in mice. We show that iTAP/Frmd8 KO mice exhibit defects in inflammatory and intestinal epithelial barrier repair functions, but not the collateral defects associated with global ADAM17 loss. Furthermore, we show that iTAP/Frmd8 regulates cancer cell growth in a cell-autonomous manner and by modulating the tumor microenvironment. Our work suggests that pharmacological intervention at the level of iTAP/Frmd8 may be beneficial to target ADAM17 activity in specific compartments during chronic inflammatory diseases or cancer, while avoiding the collateral impact on the vital functions associated with the widespread inhibition of ADAM17.
- Open Access
- 1 November 2020
- Published by Wiley in The FEBS Journal
- Vol. 287 (21) , 4602-4606
Crosstalk between metabolism and immunity: the 3rd Annual Research Symposium of Instituto Gulbenkian de Ciencia
The 'Crosstalks of immunity and metabolism' Symposium was focused on how the intercommunication between different organs and the immune system affects organismal health. At this meeting, experts in immunology and metabolic research provided novel insights into the growing field of immunometabolism. This report attempts to review and integrate views, ideas, propositions, and conclusions that emanated from the symposium.
- 1 November 2020
- Published by Wiley in The FEBS Journal
- Vol. 287 (21) , 4602-4606
Open AccessCrosstalk between metabolism and immunity: the 3rd Annual Research Symposium of Instituto Gulbenkian de Ciencia
The 'Crosstalks of immunity and metabolism' Symposium was focused on how the intercommunication between different organs and the immune system affects organismal health. At this meeting, experts in immunology and metabolic research provided novel insights into the growing field of immunometabolism. This report attempts to review and integrate views, ideas, propositions, and conclusions that emanated from the symposium.
- Open Access
- 1 January 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 31, 67-84
Deletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis
- 1 January 2020
- Published by Elsevier in Molecular Metabolism
- Vol. 31, 67-84
Open AccessDeletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis
- 29 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (605) , eaaz0444
iRhom2 and TNF: Partners or enemies?
IRhom2 inhibits proinflammatory signaling that stimulates liver fibrosis (Sundaram et al. , in 29 October 2019 issue).
- 29 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (605) , eaaz0444
iRhom2 and TNF: Partners or enemies?
IRhom2 inhibits proinflammatory signaling that stimulates liver fibrosis (Sundaram et al. , in 29 October 2019 issue).